Big Pharma has been reporting Qtr 4 earning this week and makng its projections for 2011. Earnings n Qtr 4 have been mixed in terms of hitting analysts expectations, but a more unamimous picture is emerging based on CEO comments for 2011.
The consensus seems to be one of increasing generics pressure, depressing effects from US healthcare reforms and price cuts from government controls. That leads to most CEOs pointing to the low end of the ranges they provide analysts for guidance on earnings in 2011. It's looking like flat to 3% increases in earnings are the consensus for now. See Reuters here and here.
Posted by Bruce Lehr Jan 27th 2011.
Comments